TW201643163A - 純化之吡咯并喹啉基-吡咯啶-２，５-二酮組成物以及製造與使用彼之方法 - Google Patents
純化之吡咯并喹啉基-吡咯啶-２，５-二酮組成物以及製造與使用彼之方法 Download PDFInfo
- Publication number
- TW201643163A TW201643163A TW105127477A TW105127477A TW201643163A TW 201643163 A TW201643163 A TW 201643163A TW 105127477 A TW105127477 A TW 105127477A TW 105127477 A TW105127477 A TW 105127477A TW 201643163 A TW201643163 A TW 201643163A
- Authority
- TW
- Taiwan
- Prior art keywords
- dione
- dihydro
- pyrrolo
- trans
- quinolin
- Prior art date
Links
- UCEQXRCJXIVODC-ANYOKISRSA-N O=C(C([C@@H]1c2c[n]3c4c2cccc4CCC3)c2c[nH]c3ccccc23)NC1=O Chemical compound O=C(C([C@@H]1c2c[n]3c4c2cccc4CCC3)c2c[nH]c3ccccc23)NC1=O UCEQXRCJXIVODC-ANYOKISRSA-N 0.000 description 1
- KHOMTMSVRMPSGP-UHFFFAOYSA-N O=C(C(c1c[nH]c2ccccc12)=C1c2c[n](CCC3)c4c3cccc24)NC1=O Chemical compound O=C(C(c1c[nH]c2ccccc12)=C1c2c[n](CCC3)c4c3cccc24)NC1=O KHOMTMSVRMPSGP-UHFFFAOYSA-N 0.000 description 1
- UCEQXRCJXIVODC-UXHICEINSA-N O=C([C@@H]([C@@H]1c2c[n]3c4c2cccc4CCC3)c2c[nH]c3ccccc23)NC1=O Chemical compound O=C([C@@H]([C@@H]1c2c[n]3c4c2cccc4CCC3)c2c[nH]c3ccccc23)NC1=O UCEQXRCJXIVODC-UXHICEINSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/06—Peri-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28956309P | 2009-12-23 | 2009-12-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW201643163A true TW201643163A (zh) | 2016-12-16 |
Family
ID=44188284
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW105127477A TW201643163A (zh) | 2009-12-23 | 2010-12-22 | 純化之吡咯并喹啉基-吡咯啶-２，５-二酮組成物以及製造與使用彼之方法 |
| TW104125790A TWI557125B (zh) | 2009-12-23 | 2010-12-22 | 純化之吡咯并喹啉基-吡咯啶-２，５-二酮組成物以及製造與使用彼之方法 |
| TW099145242A TWI506026B (zh) | 2009-12-23 | 2010-12-22 | 純化之吡咯并喹啉基－吡咯啶－２，５－二酮組成物以及製造與使用彼之方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW104125790A TWI557125B (zh) | 2009-12-23 | 2010-12-22 | 純化之吡咯并喹啉基-吡咯啶-２，５-二酮組成物以及製造與使用彼之方法 |
| TW099145242A TWI506026B (zh) | 2009-12-23 | 2010-12-22 | 純化之吡咯并喹啉基－吡咯啶－２，５－二酮組成物以及製造與使用彼之方法 |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US8552192B2 (https=) |
| EP (2) | EP2515904A4 (https=) |
| JP (2) | JP2013515737A (https=) |
| KR (2) | KR20160121602A (https=) |
| CN (2) | CN104910159A (https=) |
| AU (2) | AU2010336533B9 (https=) |
| BR (1) | BR112012015656A2 (https=) |
| CA (1) | CA2785503A1 (https=) |
| CO (1) | CO6561823A2 (https=) |
| HK (1) | HK1215025A1 (https=) |
| MX (1) | MX2012007259A (https=) |
| MY (2) | MY156701A (https=) |
| NZ (2) | NZ600800A (https=) |
| PH (2) | PH12012501293A1 (https=) |
| RU (1) | RU2556205C2 (https=) |
| SG (1) | SG181927A1 (https=) |
| TW (3) | TW201643163A (https=) |
| WO (1) | WO2011079142A2 (https=) |
| ZA (1) | ZA201204759B (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE486872T1 (de) * | 2005-02-09 | 2010-11-15 | Arqule Inc | Maleimid-derivate, pharmazeutische zusammensetzungen und verfahren zur behandlung von krebs |
| PH12012501293A1 (en) * | 2009-12-23 | 2013-01-07 | Arqule Inc | Purified pyrroloquinolinyl-pyrrolidine-2,5-dione compositions and methods for preparing and using same |
| MX2014000253A (es) * | 2011-07-07 | 2014-10-17 | Arqule Inc | Formulaciones de pirroloquinolinil-pirrolidin-2,5-diona y metodos para preparar y utilizar las mismas. |
| WO2013162714A1 (en) * | 2012-04-23 | 2013-10-31 | Arqule, Inc. | Highly pure pyrroloquinolinyl-pyrrole-2,5-dione and pyrroloquinolinyl-pyrrolidine-2,5-dione and methods of preparing same |
| US9688682B2 (en) * | 2013-07-16 | 2017-06-27 | Dr. Reddy's Laboratories Limited | Crystalline forms of pemetrexed tromethamine salts |
| EP3665176B1 (en) | 2017-08-11 | 2024-01-24 | Actuate Therapeutics Inc. | Solid forms of 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5h[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione |
| CN110806454A (zh) * | 2018-08-06 | 2020-02-18 | 江苏正大清江制药有限公司 | 一种盐酸吉西他滨中手性异构体的检测方法 |
| US20220143049A1 (en) | 2019-03-21 | 2022-05-12 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| EP4054579A1 (en) | 2019-11-08 | 2022-09-14 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| IL307471A (en) * | 2021-04-07 | 2023-12-01 | Ur 1 Therapeutics Inc | URAT1 inhibitor, pharmaceutical preparations and their uses |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| DE4128015A1 (de) * | 1991-08-23 | 1993-02-25 | Kali Chemie Pharma Gmbh | 1,7-anellierte 2-(piperazinoalkyl)indol-derivate sowie verfahren und zwischenprodukte zu ihrer herstellung und diese verbindugnen enthaltende arzneimittel |
| US5760237A (en) * | 1995-08-25 | 1998-06-02 | California Institute Of Technology | Synthesis of l-azatyrosine using pseudoephedrine as a chiral auxiliary |
| WO2001044247A2 (en) * | 1999-12-16 | 2001-06-21 | Eli Lilly And Company | Agents and methods for the treatment of proliferative diseases |
| EP1527034B1 (en) * | 2002-07-31 | 2006-01-04 | Firmenich Sa | A process for the optical resolution of a precursor of sclareolide |
| CA2573508A1 (en) * | 2004-09-10 | 2006-03-23 | Wyeth | Process for the scalable synthesis of 1, 3, 4, 9-tetrahydropyrano[3, 4-b]-indole derivatives |
| ATE486872T1 (de) * | 2005-02-09 | 2010-11-15 | Arqule Inc | Maleimid-derivate, pharmazeutische zusammensetzungen und verfahren zur behandlung von krebs |
| US20070185346A1 (en) * | 2006-02-03 | 2007-08-09 | Vaidya Niteen A | Kit for automated resolving agent selection and method thereof |
| WO2009002806A1 (en) | 2007-06-22 | 2008-12-31 | Arqule, Inc. | Pyrrolidinone, pyrrolidine-2, 5-dione, pyrrolidine and thiosuccinimide derivatives, compositions and methods for treatment of cancer |
| EP2392574B1 (en) * | 2007-06-22 | 2013-12-18 | ArQule, Inc. | Indolyl pyrrolidines for the treatment of cancer |
| PH12012501293A1 (en) * | 2009-12-23 | 2013-01-07 | Arqule Inc | Purified pyrroloquinolinyl-pyrrolidine-2,5-dione compositions and methods for preparing and using same |
| WO2013162714A1 (en) * | 2012-04-23 | 2013-10-31 | Arqule, Inc. | Highly pure pyrroloquinolinyl-pyrrole-2,5-dione and pyrroloquinolinyl-pyrrolidine-2,5-dione and methods of preparing same |
-
2010
- 2010-12-21 PH PH1/2012/501293A patent/PH12012501293A1/en unknown
- 2010-12-21 KR KR1020167027918A patent/KR20160121602A/ko not_active Ceased
- 2010-12-21 CN CN201510243421.1A patent/CN104910159A/zh active Pending
- 2010-12-21 RU RU2012131344/04A patent/RU2556205C2/ru active
- 2010-12-21 KR KR1020127019155A patent/KR101669707B1/ko active Active
- 2010-12-21 JP JP2012546161A patent/JP2013515737A/ja active Pending
- 2010-12-21 WO PCT/US2010/061625 patent/WO2011079142A2/en not_active Ceased
- 2010-12-21 NZ NZ600800A patent/NZ600800A/en unknown
- 2010-12-21 MY MYPI2012002895A patent/MY156701A/en unknown
- 2010-12-21 EP EP10840083.9A patent/EP2515904A4/en not_active Ceased
- 2010-12-21 SG SG2012047023A patent/SG181927A1/en unknown
- 2010-12-21 AU AU2010336533A patent/AU2010336533B9/en active Active
- 2010-12-21 NZ NZ628087A patent/NZ628087A/en unknown
- 2010-12-21 CN CN201080064457.9A patent/CN102834097B/zh active Active
- 2010-12-21 MY MYPI2014003506A patent/MY169232A/en unknown
- 2010-12-21 BR BR112012015656A patent/BR112012015656A2/pt not_active IP Right Cessation
- 2010-12-21 EP EP16168527.6A patent/EP3081567A3/en not_active Withdrawn
- 2010-12-21 MX MX2012007259A patent/MX2012007259A/es unknown
- 2010-12-21 CA CA2785503A patent/CA2785503A1/en not_active Abandoned
- 2010-12-22 TW TW105127477A patent/TW201643163A/zh unknown
- 2010-12-22 TW TW104125790A patent/TWI557125B/zh active
- 2010-12-22 US US12/975,644 patent/US8552192B2/en active Active
- 2010-12-22 TW TW099145242A patent/TWI506026B/zh active
-
2012
- 2012-06-26 ZA ZA2012/04759A patent/ZA201204759B/en unknown
- 2012-07-23 CO CO12122679A patent/CO6561823A2/es active IP Right Grant
-
2013
- 2013-09-25 US US14/036,672 patent/US8871933B2/en active Active
-
2014
- 2014-02-06 PH PH12014500310A patent/PH12014500310A1/en unknown
- 2014-09-26 US US14/498,651 patent/US9499540B2/en active Active
-
2015
- 2015-10-07 JP JP2015198998A patent/JP2016041712A/ja active Pending
- 2015-10-14 AU AU2015243015A patent/AU2015243015B2/en active Active
-
2016
- 2016-03-16 HK HK16103027.3A patent/HK1215025A1/zh unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI557125B (zh) | 純化之吡咯并喹啉基-吡咯啶-２，５-二酮組成物以及製造與使用彼之方法 | |
| JP2022140637A (ja) | 結晶性（８Ｓ，９Ｒ）－５－フルオロ－８－（４－フルオロフェニル）－９－（１－メチル－１Ｈ－１，２，４－トリアゾール－５－イル）－８，９－ジヒドロ－２Ｈ－ピリド［４，３，２－ｄｅ］フタラジン－３（７Ｈ）－オントシレート塩 | |
| AU2015257456B2 (en) | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer | |
| JP6046710B2 (ja) | 置換されたイミダゾピリジニル−アミノピリジン化合物 | |
| CN107074769B (zh) | 用于治疗增生性病症的组合物和方法 | |
| JP2017190337A (ja) | がんを処置するための組合せ治療 | |
| JP2019503391A (ja) | 癌を処置するための併用療法 | |
| CN116490188B (zh) | 含氮杂环类衍生物的盐、晶型及其制备方法和应用 | |
| EP4353724A1 (en) | Compound as cdk kinase inhibitor and use thereof | |
| US20110160226A1 (en) | Substituted Triazolo-Pyrimidine Compounds | |
| CN104884456B (zh) | PI3K和/或mTOR抑制剂 | |
| JP5984837B2 (ja) | ピロロキノリニル−ピロリジン−２，５−ジオン組成物ならびにそれを調製および使用する方法 | |
| JP2026048692A (ja) | Ｓｒｃキナーゼの阻害、ならびに関連障害の処置及び予防において使用するための組成物 | |
| JP2026503067A (ja) | ２－メチル－２－（３－（ピペリジン－３－イル）フェノキシ）－２－メチルプロパンアミド骨格含有化合物 |